Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-20 inclisiran study in children with heterozygous familial hypercholesterolemia
CTR20250165Phase 3Active
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in heterozygous familial hypercholesterolemia (HeFH), sponsored by Novartis. Started Jun 2025; status: active.
02
Drugs
inclisiran
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on CTR20250165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250165.